BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BC Extra | Dec 11, 2019
Clinical News

AstraZeneca, Daiichi’s trastuzumab ADC sets new efficacy bar in breast cancer

Trastuzumab deruxtecan from AstraZeneca and Daiichi Sankyo may have established a new threshold for efficacy in HER2+ breast cancer based on pivotal Phase II data. The data were better, in a sicker patient population, than...
BC Extra | Oct 21, 2019
Clinical News

Seattle Genetics at all-time high on strength of breast cancer readout

Seattle Genetics added more than $2 billion in market cap Monday after reporting pivotal survival data for breast cancer therapy tucatinib, a TKI targeting HER2 which is designed to have a favorable toxicity profile compared...
BC Week In Review | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

China is exempting 12 cancer drugs from tariffs imposed on U.S. goods, the first time China has offered tariff relief since the trade war began last year. The 12 drugs include Iressa gefitinib and Tomudex...
BC Extra | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
BC Extra | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
BioCentury | Feb 1, 2019
Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
BC Week In Review | Jan 18, 2019
Company News

Proteus launches digital oral chemo management system

Proteus Digital Health Inc. (Redwood City, Calif.) launched a digital cancer medicine system to help manage oral chemotherapy treatment of stage 3 and 4 colorectal cancer patients. The system, which was developed with the University...
BioCentury | Oct 6, 2018

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 31, 2018
Clinical News

China approves Hengrui breast cancer drug on Phase II data

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China’s State Drug Administration conditionally approved pyrotinib (SHR-1258, HTI-1001) in combination with capecitabine to treat HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or...
Items per page:
1 - 10 of 518